MGTX.US MeiraGTx Holdings PLC

Healthcare Biotechnology USA Stocks
8.74 USD
Close of Nov 16, 2026
6.62 15.35
Market cap
USD 854M
P/E
10.0x
P/B
4.18x
ROE
39.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MGTX.US undervalued?

Graham number
Price8.74
Graham value6.40
Premium36.6%

MGTX.US trades 36.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MeiraGTx Holdings PLC fundamental analysis

No fundamental analysis for MeiraGTx Holdings PLC yet.

MeiraGTx Holdings PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MeiraGTx Holdings PLC

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkin…

Full company profile